== Extra material== 
 I'm removing this from the article: 

 In June 2006, Mannatech signed a research agreement with Hyperion Biotechnology, Inc., in which Mannatech agreed to fund a research study related to Ambrotose.Mannatech, Incorporated, Form 10K SEC Public Filing for FY 2006 Retrieved on April 14, 2007.  In 2005, the Small Business Administration (SBA) of the U.S. federal government certified Hyperion Biotechnology as a "small disadvantaged business"Hyperion Biotechnology Corporate Web Site, About Us Retrieved on April 14, 2007. under the SBA's 8(a) Business Development Program on the basis that Hyperion Biotechnology is a "socially and economically disadvantaged"U.S. Department of Commerce, Office of Small and Disadvantaged Business Utilization, Information for Small Disadvantaged and 8(a) Small Businesses Retrieved on April 14, 2007. firm.  
 
 In December 2006, Mannatech signed a research agreement with St. George's Hospital & Medical School, in London, England to aid in the funding of a "three-year clinical trial related to dosing and optimization study" on Ambrotose."Mannatech, Incorporated, Form 10K SEC Public Filing for FY 2006 Retrieved on April 14, 2007. 

  
 The information about Hyperion is immaterial, and the remainder doesn't contribute to the content of the article. It just lists things that Mannatech has done. I left the press release, because it made an actual statement, but the rest of this is unwarranted in this article.